跳转至内容
Merck
CN

GE17-0618-05

Protein G Sepharose™ 4 Fast Flow

Cytiva 17-0618-05, pack of 200 mL

别名:

Fast Flow resin, Antibody purification resin, IgG purification resin

登录 查看组织和合同定价。

选择尺寸

关于此项目

NACRES:
NA.56
UNSPSC Code:
41106500

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Protein G Sepharose™ 4 Fast Flow, Cytiva 17-0618-05, pack of 200 mL

form

resin

crosslinking

cross-linked

packaging

pack of 200 mL

manufacturer/tradename

Cytiva 17-0618-05

storage condition

(20% Ehtanol)

parameter

<0.1 Mpa pressure
150-250 cm/hr flow rate

technique(s)

liquid chromatography (LC): suitable

matrix

4% cross-linked agarose

matrix active group

Recombinant streptococcal protein G lacking the albumin-binding region, produced in E. coli

average diameter

90 μm (d50v)

cleaning in place

2-10

working range

3-9

capacity

≥20 mg binding capacity(human IgG/mL resin)

separation technique

affinity

storage temp.

2-8°C

相关类别

Analysis Note

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Features and Benefits

  • Binding specificities that complement Protein A media.
  • Binds a broad range of IgG species and subclasses.
  • Multi-point attachment minimizes ligand leakage.
  • Used in a range of research applications.

General description

Protein G Sepharose™ 4 Fast Flow is recombinant protein G coupled to Sepharose™ 4 Fast Flow.

Protein G Sepharose™ 4 Fast Flow has recombinant protein G immobilized by the cyanogen bromide (CNBr) method to Sepharose™ 4 Fast Flow. Protein G exhibit binding specificities that complement Protein A media and binds to the Fc region of IgG from a variety of mammalian species. Protein G Sepharose™ 4 Fast Flow may be used to isolate and purify classes, subclasses and fragments of immunoglobulins from any biological fluid or cell culture medium.

As member of the BioProcess media range, Protein G Sepharose™ 4 Fast Flow meets industrial demands with security of supply and comprehensive technical and regulatory support.

Preparation Note

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.

Legal Information

Sepharose is a trademark of Cytiva

pictograms

Flame
GHS02

signalword

Warning

hcodes

H226

存储类别

3 - Flammable liquids

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
Sara E Vazquez et al.
Journal of clinical immunology, 41(6), 1169-1171 (2021-05-20)
Kanika Vanshylla et al.
Cell host & microbe, 29(6), 917-929 (2021-05-14)
Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4%
Monique G P van der Wijst et al.
bioRxiv : the preprint server for biology (2021-03-25)
Type I interferon (IFN-I) neutralizing autoantibodies have been found in some critical COVID-19 patients; however, their prevalence and longitudinal dynamics across the disease severity scale, and functional effects on circulating leukocytes remain unknown. Here, in 284 COVID-19 patients, we found
Kanika Vanshylla et al.
Cell host & microbe, 30(1), 69-82 (2022-01-02)
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we performed single B cell analysis from 10 SARS-CoV-2 elite neutralizers. We isolated and analyzed 126
Monique G P van der Wijst et al.
Science translational medicine, 13(612), eabh2624-eabh2624 (2021-08-26)
Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynamics across
查看所有相关文献

商品

Desalting and Buffer Exchange for Affinity Chromatography of Antibodies

Desalting at laboratory scale is a well-proven, simple, and fast method that will rapidly remove low molecular weight contaminants at the same time as transferring the sample into the desired buffer in a single step.

Immunoprecipitation Techniques

This page describes immunoprecipitation (immunoaffinity or pull-down techniques).

Affinity Chromatography Troubleshooting

This page shows how to solve practical problems that may occur when running an affinity chromatography column.

Column Packing and Preparation for Affinity Chromatography of Antibodies

This page describes efficient column packing and preparation for affinity chromatography of antibodies.

查看所有结果

实验方案

Performing a Purification of IgG Antibodies with Protein G Sepharose® 4 Fast Flow

This page shows how to separate IgG antibodies by affinity chromatography using Protein G Sepharose 4 Fast Flow from Cytiva.

Sample Preparation for Affinity Chromatography

This page shows how to prepare samples for purification with affinity chromatography.

Pull-down assays

This page provides information about different pull-down assays for the further isolation of multiprotein complexes to identify their components with products from Cytiva.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持